| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 7862190 | Journal of Controlled Release | 2016 | 13 Pages |
Abstract
HA-NPs and HA-LPs have been developed to be selectively taken up by CD44+ tumor cells, which greatly improved antitumor efficacy and reduced systemic adverse effects in treating CD44+ cancer.301
Related Topics
Physical Sciences and Engineering
Materials Science
Biomaterials
Authors
Wenhao Li, Xiaoli Yi, Xing Liu, Zhirong Zhang, Yao Fu, Tao Gong,